Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues

Autor: Dustin E Bosch, Melissa Lerch, Lei Zhao, Pei Wang, Laura C Kennedy, Kimberly H. Allison, Andrew N. Hoofnagle, Regine M. Schoenherr, Amanda G. Paulovich, Chenwei Lin, Mark R. Kilgore, Jacob J. Kennedy, Jeffrey R. Whiteaker, Geoffrey S. Baird, Shrabanti Chowdhury

Publikováno v: Clin Chem

Background Conventional HER2-targeting therapies improve outcomes for patients with HER2-positive breast cancer (BC), defined as tumors showing HER2 protein overexpression by immunohistochemistry and/or ERBB2 gene amplification determined by in situ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31085dee97ecfd64d8e01d946b1047ec
https://doi.org/10.1093/clinchem/hvab047

Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications

Autor: Petr Steiner, Alena Skálová, Petr Martinek, Martina Baněčková, Andrle Pavel, Thalita Santana, Petr Grossmann

Publikováno v: Human Pathology. 93:37-47

Summary Salivary duct carcinoma (SDC) is one of the most aggressive salivary gland tumors, and prognosis remains poor for most patients. The aim of this study was to investigate the prognostic implications of biomarker immunoprofile in a cohort of SD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc3f47821dfe5ecf22b32069df90ea80
https://doi.org/10.1016/j.humpath.2019.08.009

Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification

Autor: Jaffer A. Ajani, Xuemei Wang, Allison Trail, Meina Zhao, Jeannelyn S. Estrella, Jane E. Rogers, Ahmed K. Abdelhakeem, Mariela Blum-Murphy

Publikováno v: Oncology. 98(12)

Background: Prior studies have shown that patients whose tumor overexpresses Her2 at 3+ level by immunohistochemistry (IHC) fare better than those whose tumor overexpresses Her2 at 2+ level (with ERBB2 amplified). Therefore, it would be important to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b1f82372bec9e2dfcec2f2d5f40782e
https://pubmed.ncbi.nlm.nih.gov/32998149

Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab

Autor: Mauro Frigeri, Alexandre Bodmer, Krisztian Homicsko, Jean-Christophe Tille, Olivier Michielin, Thomas Alexander Mckee, Yann Christinat, Petros Tsantoulis, Laure Thouvenin, Sophie Clément, Pierre O. Chappuis, Melinda Charrier

Publikováno v: Gynecologic Oncology Reports
Gynecologic Oncology Reports, Vol 37, Iss, Pp 100787-(2021)
Gynecologic oncology reports, vol. 37, pp. 100787
Gynecologic Oncology Reports, Vol. 37 (2021) P. 100787

Highlights • Trastuzumab monotherapy has limited efficacy in ovarian cancer. • The combination of trastuzumab and pertuzumab has not been studied adequately. • An ERBB2-amplified ovarian carcinoma had a durable response to this combination. •

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c295064b33afba194517ef22e0972280
https://doi.org/10.1016/j.gore.2021.100787

Automatic quantification of HER2 gene amplification in invasive breast cancer from chromogenic in situ hybridization whole slide images

Autor: Shakhawat Hossain, Edi Brogi, Naohiro Uraoka, Yukako Yagi, Meera Hameed, Marcia Edelweiss, Tomoya Nakamura, Dara S. Ross, Masahiro Yamaguchi, Matthew G. Hanna

Publikováno v: J Med Imaging (Bellingham)

Human epidermal growth factor receptor 2 (HER2), a transmembrane tyrosine kinase receptor encoded by the ERBB2 gene on chromosome 17q12, is a predictive and prognostic biomarker in invasive breast cancer (BC). Approximately 20% of BC are HER2-positiv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3ec54b2764c33d0a0de4499b00e12b7
https://europepmc.org/articles/PMC6868351/